DSGN (Design Therapeutics) Prakiraan volume dodolan
The development of R&D centers and collaboration with contract manufacturing organizations enable the scaling of production for Design Therapeutics (DSGN). The company's sales targets confirm this growth, with the current figure standing at 0.00. Safe methods for correcting genetic defects create a competitive advantage, while financial stability is based on the successful validation of the therapeutic platform and the acquisition of strategic partners.
Design Pharma - rincian analitis lan metrik utama (DSGN)
- kuotasi lan prakiraan analis:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Design Therapeutics|DSGN - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal Design Therapeutics Inc|DSGN - Utang kumulatif perusahaan|Utang marang nilai buku Design Pharma|DSGN - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Design Therapeutics|Rasio cepet designtx.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
DSGN - Asil keuangan resik|Proyeksi bathi mangsa ngarep Design Therapeutics|DSGN - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Design Corp|DSGN - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Design Therapeutics, Inc.|DSGN - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Design Therapeutics|DSGN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan designtx.com|DSGN - Owah-owahan bathi resik saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Design Therapeutics
- informasi babagan volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:designtx.com DSGN
For investors in Design Therapeutics (DSGN), it is critical to assess the commercialization potential of GeneTACS technologies within the emerging gene regulation ecosystem. An analysis of financial sales expectations captures the daily market consensus regarding future revenue from rare pathology therapies, allowing for the determination of the asset monetization vector and an assessment of the risks of long-term capital freeze amid macroeconomic volatility.
Analisis perusahaan pesaing
Volume dodolan mangsa ngarep perusahaan TEM (Tempus AI)|Dodolan mangsa ngarep perusahaan Qiagen Group|Prakiraan pendapatan perusahaan Ionis Pharma IONS|RGEN - Volume dodolan mangsa ngarep perusahaan|RNA - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan RARE (Ultragenyx)|Volume dodolan mangsa ngarep perusahaan BEAM|Prakiraan volume dodolan Sarepta Corp|Prakiraan pendapatan perusahaan Twist Bioscience, Inc. (TWST)|Volume dodolan mangsa ngarep perusahaan 10x Genomics TXG|Prakiraan pendapatan perusahaan Intellia Therapeutics NTLA|Prakiraan volume pendapatan perusahaan STOK (Stoke Therapeutics, Inc.)|BLFS - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Wave Pharma|mazetx.com (MAZE) - Prakiraan pendapatan perusahaan|SION - Dodolan mangsa ngarep perusahaan|PRME (Prime Medicine Inc) - Prakiraan volume dodolan|Taysha Gene Therapies, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan QURE|MGTX: Pendapatan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan REGENXBIO RGNX|SLDB: Prakiraan pendapatan perusahaan|OCGN: Volume dodolan mangsa ngarep perusahaan|PACB - Prakiraan volume dodolan|BNTC (Benitec Corp) - Volume dodolan mangsa ngarep perusahaan|RCKT - Dodolan mangsa ngarep perusahaan|FDMT: Dodolan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan LXEO (lexeotx.com)|Prakiraan pendapatan perusahaan Korro Bio Inc. (KRRO)|Prakiraan volume pendapatan perusahaan EDIT|Prakiraan volume dodolan SLN (Silence Therapeutics PLC)|Pendapatan mangsa ngarep perusahaan PRQR|CDXS - Prakiraan pendapatan perusahaan|SGMO (Sangamo Therapeutics) - Prakiraan pendapatan perusahaan|NAUT: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan MGX|DTIL (precisionbiosciences.com) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GBIO (Generation Bio Co.)|Prakiraan pendapatan perusahaan Boundless Bio (BOLD)|Exicure - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan IMNN (imunon.com)|Dodolan mangsa ngarep perusahaan Phio Pharmaceuticals (PHIO)|MBIO: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Prakiraan pendapatan perusahaan|APDN - Dodolan mangsa ngarep perusahaan|Volume dodolan mangsa ngarep perusahaan BLUE|Prakiraan volume dodolan immunoprecise.com|Prakiraan volume dodolan OMGA|Dodolan mangsa ngarep perusahaan Singular Genomics Corp|Regulus Therapeutics - Volume dodolan mangsa ngarep perusahaan|SYRS (Syros Pharmaceuticals) - Pendapatan sing dikarepake perusahaan|Telesis Bio Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan TCON (TRACON Pharmaceuticals Inc.)|UBX: Prakiraan volume dodolan
